Company Performance Metrics
Michael Macaluso: Founder & CEOPast Role: Page International Communications, Owner
David Bar: CSOPast Role: Swedish Medical Center, Director of Trauma Research
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs selected from its extensive portfolio with the potential to be safe and effective for improving patient care. The company’s product pipeline includes new uses for approved drugs and new molecular entities (“NMEs”) for important therapeutic areas, including metabolic disease, eye
disease, kidney disease, inflammation, sexual dysfunction and CNS disease.
Central to the company’s successful clinical development programs are its strong relationships with clinicians, academic medical centers, regional hospitals and specialized product and service providers. A phase II clinical development program is underway in addition to sponsored basic, translational and clinical research projects aimed at specific disease mechanisms. The company has built a robust portfolio of issued patents and pending patent applications on its products.
